RxDoctor Payments Data

Vladlen Kim, MD

Internal Medicine · Lyndhurst, OHNPI 1770557506

Payments from drug & device makers

$32,489in general payments, 2019–2025

Across 344 payments — averaging $94.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$18K
  • Phathom Pharmaceuticals, Inc.$9K
  • AbbVie$1K
  • Amgen$864
  • Pfizer$559
  • E.r. Squibb & Sons, L.L.C.$374
  • plus $3K from 35 others

What the payments were for

  • Speaking & faculty fees$24,46075%
  • Travel & lodging$3561%
  • Food & beverage$7,62523%
  • Education$480%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,489 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$143,516
Medicare patients
475
Services billed
3,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban306$299,295
OzempicSemaglutide118$134,089
JardianceEmpagliflozin105$120,986
TrulicityDulaglutide87$98,953
JanuviaSitagliptin Phosphate79$86,752
FarxigaDapagliflozin Propanediol85$72,869
XareltoRivaroxaban48$60,945
LinzessLinaclotide85$52,046
CreonLipase/Protease/Amylase46$42,662
MyrbetriqMirabegron38$41,553
MounjaroTirzepatide27$27,545
EntrestoSacubitril/Valsartan19$22,059
InvokanaCanagliflozin32$21,372
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$18,283
KerendiaFinerenone16$15,476

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$559$299,295306 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$150$143,146141 claims
Novo NordiskOzempic$236$134,089118 claims
Lilly USA, LLCTrulicity, Mounjaro$153$126,498114 claims
AstraZenecaFarxiga, Nexium, Symbicort$17,970$96,113146 claims
AbbVieLinzess, Creon$1,087$94,708131 claims
MerckJanuvia$187$86,75279 claims
Johnson & JohnsonXarelto, Invokana$77$82,31780 claims
Astellas Pharma US IncMyrbetriq$138$41,55338 claims
GSKTrelegy Ellipta, Breo Ellipta$132$23,11136 claims
NovartisEntresto$56$22,05919 claims
BayerKerendia$103$15,47616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Lyndhurst

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →